文献速递血液净化与透析

常规或延长血液透析及血液透析滤过对终末期肾病患者血浆草酸盐浓度的影响

Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease.
PubMed 文献 · Kidney Int Rep · 2017-06-08

结果显示透析中POx降低约90%,HD与HDF无显著差异,延长治疗时间亦无额外获益,提示需重新评估传统HDF优于HD的策略。

要点

  • HD与HDF对POx的降低效果无显著差异。
  • 延长透析时间未进一步改善POx清除。
  • 透析后POx存在约2.1 μmol/l的反跳。

核心结论

  • 与既往观察相反,本研究不支持HDF在降低POx方面优于HD。
  • 延长治疗时间未带来额外获益,需重新评估优化尿毒症毒素清除的传统方案。

研究设计与样本

  • 患者分为常规HDF组(每次4–4.5小时,n=8)和延长HDF组(每次7–7.5小时,n=6)。
  • 干预顺序为HDF转HD 2周,再转回HDF 2周,在基线、透析前、中、后及透析后2小时测量POx。

主要发现

  • 全部患者基线POx平均为28.0 ± 7.0 μmol/l。
  • 透析中POx降低约90%,组间及治疗模式间无显著差异[F(1)=0.63;P=0.44]。
  • 透析后POx平均为3.3 ± 1.8 μmol/l,透析后2小时内反跳2.1 ± 1.9 μmol/l。
  • 治疗2周后,HD与HDF的透析前POx无显著差异[F(1)=0.21;P=0.66]。
  • 延长治疗时间未提供额外获益[F(1)=0.76;P=0.40]。

临床怎么用

  • 对于终末期肾病患者,HD与HDF在降低POx方面效果相当,选择透析模式时无需仅基于POx清除考虑HDF。
  • 延长透析时间未显示额外降低POx的获益,个体化制定透析方案时应综合评估。

局限性

  • 研究仅观察2周干预效果,长期影响未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Calcium oxalate supersaturation is regularly exceeded in the plasma of patients with end-stage renal disease (ESRD). Previous reports have indicated that hemodialfiltration (HDF) lowers elevated plasma oxalate (POx) concentrations more effectively compared with hemodialysis (HD). We reevaluate the therapeutic strategy for optimized POx reduction with advanced dialysis equipment and provide data on the effect of extended treatment time on dialytic oxalate kinetics. METHODS: Fourteen patients with ESRD who underwent HDF 3 times a week for 4 to 4.5 hours (regular HDF; n = 8) or 7 to 7.5 hours (extended HDF; n = 6) were changed to HD for 2 weeks and then back to HDF for another 2 weeks. POx was measured at baseline, pre-, mid-, and postdialysis, and 2 hours after completion of the treatment session. RESULTS: Baseline POx for all patients averaged 28.0 ± 7.0 μmol/l. Intradialytic POx reduction was approximately 90% and was not significantly different between groups or treatment modes [F(1) = 0.63; P = 0.44]. Mean postdialysis POx concentrations were 3.3 ± 1.8 μmol/l. A rebound of 2.1 ± 1.9 μmol/l was observed within 2 hours after dialysis. After receiving 2 weeks of the respective treatment, predialysis POx concentrations on HD did not differ significantly from those on HDF [F(1) = 0.21; P = 0.66]. Extended treatment time did not provide any added benefit [F(1) = 0.76; P = 0.40]. DISCUSSION: In contrast to earlier observations, our data did not support a benefit of HDF over HD for POx reduction. With new technologies evolving, our results emphasized the need to carefully reevaluate and update traditional therapeutic regimens for optimized uremic toxin removal, including those used for oxalate.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Ermer T, Kopp C, Asplin JR, et al. Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease. Kidney Int Rep. 2017. PMID: 29270514. doi:10.1016/j.ekir.2017.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。